P/E ratio for Regeneron Pharmaceuticals (REGN)
P/E ratio as of June 2025 (TTM): 12.6
According to Regeneron Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.5904. At the end of 2024 the company had a P/E ratio of 17.4.
P/E ratio history for Regeneron Pharmaceuticals from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 17.4 | -26.49% |
| 2023 | 23.7 | 33.13% |
| 2022 | 17.8 | 115.55% |
| 2021 | 8.26 | -43.98% |
| 2020 | 14.7 | -23.92% |
| 2019 | 19.4 | 17.5% |
| 2018 | 16.5 | -50.5% |
| 2017 | 33.3 | -22.28% |
| 2016 | 42.9 | -51.34% |
| 2015 | 88.1 | -23.31% |
| 2014 | 115 | 80.78% |
| 2013 | 63.6 | 192.43% |
| 2012 | 21.7 | |
| 2010 | -25.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 26.8 | 112.98% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -156 | -1,338.27% | 🇺🇸 USA |
 Biogen BIIB | 12.9 | 2.84% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 17.4 | 37.83% | 🇺🇸 USA |
 Novartis NVS | 18.6 | 47.85% | 🇨🇭 Switzerland |
 Sanofi SNY | 17.5 | 39.13% | 🇫🇷 France |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.